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Background: Dysregulated expression of Kallikrein-related peptidase 6 (KLK6) is a common feature for many human
malignancies and numerous studies evaluated KLK6 as a promising biomarker for early diagnosis or unfavorable
prognosis. However, the expression of KLK6 in carcinomas derived from mucosal epithelia, including head and
neck squamous cell carcinoma (HNSCC), and its mode of action has not been addressed so far.
Methods: Stable clones of human mucosal tumor cell lines were generated with shRNA-mediated silencing or
ectopic overexpression to characterize the impact of KLK6 on tumor relevant processes in vitro. Tissue microarrays
with primary HNSCC samples from a retrospective patient cohort (n = 162) were stained by immunohistochemistry
and the correlation between KLK6 staining and survival was addressed by univariate Kaplan-Meier and multivariate
Cox proportional hazard model analysis.
Results: KLK6 expression was detected in head and neck tumor cell lines (FaDu, Cal27 and SCC25), but not in HeLa
cervix carcinoma cells. Silencing in FaDu cells and ectopic expression in HeLa cells unraveled an inhibitory function
of KLK6 on tumor cell proliferation and mobility. FaDu clones with silenced KLK6 expression displayed molecular
features resembling epithelial-to-mesenchymal transition, nuclear β-catenin accumulation and higher resistance
against irradiation. Low KLK6 protein expression in primary tumors from oropharyngeal and laryngeal SCC patients
was significantly correlated with poor progression-free (p = 0.001) and overall survival (p < 0.0005), and served as an
independent risk factor for unfavorable clinical outcome.
Conclusions: In summary, detection of low KLK6 expression in primary tumors represents a promising tool to
stratify HNSCC patients with high risk for treatment failure. These patients might benefit from restoration of KLK6
expression or pharmacological targeting of signaling pathways implicated in EMT.
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The Kallikrein-related peptidase 6 (KLK6) belongs to
a family of 15 secreted serine proteases with trypsin
or chymotrypsin-like activity [1]. KLKs are encoded
by a cluster of genes located on human chromosome
19q13.3–13.4 [2]. Deregulation of KLK6 expression
occurs in neurodegenerative and skin disorders, and
is a common event in human cancer (reviewed in [3,
4]). Most of these cancers, such as glioma, ovarian,
breast, uterine, pancreatic, colorectal, gastric, skin,
urinary bladder, lung and salivary gland tumors, were
characterized by a strong increase of KLK6 transcript
and protein levels as compared to normal tissues
(reviewed in [1, 5, 6]). Consequently, KLK6 represents a
promising biomarker of early diagnosis and/or unfavorable
prognosis in several human malignancies. Additionally,
KLK6 expression was found in tumor adjacent epithelial
and stromal cells, and may considerably contribute to
the aggressiveness of cancer cells by a paracrine mode
of action [7, 8].
Despite this overwhelming evidence pointing to a critical
role of KLK6 in neoplastic transformation and malignant
progression, the regulation and function of KLK6 under
physiological and pathological settings is poorly under-
stood. The regulation of KLK6 expression under patho-
logical conditions is most likely influenced by multiple
mechanisms, including gene copy number imbalances [9,
10], exposure to steroid hormones [11, 12], epigenetic
events such as gene promoter hyper-methylation [13–15],
oncogenic signaling [16–19], and posttranscriptional
control by miRNAs [20, 21].
KLK6 can degrade components of the extracellular
matrix in vitro and participates in cellular processes
such as inflammation, receptor activation, and regulation
of apoptosis (reviewed in [1, 3, 5]). Moreover, KLK6 is
implicated in tissue remodeling and induction of tumor-
relevant processes such as proliferation, migration and
invasion (reviewed in [1, 3]). However, recent studies
questioned the general oncogenic role of KLK6 and
stressed the importance to consider its context-dependent,
tumor-protective function, as exemplified in breast and
renal cancer [14, 22–25].
So far, the expression of KLK6 in head and neck
squamous cell carcinoma (HNSCC) and its association
with pathological features or the clinical outcome has not
been addressed in larger patient cohorts. HNSCC arise
from mucosal epithelia lining of the upper aero-digestive
tract and represent one of the most common and lethal
human cancers worldwide [26, 27]. While tobacco and
alcohol consumption remain the major risk factors, more
recent findings have established infection by high-risk
human papilloma viruses, especially HPV16, as an
important cause for a subgroup of HNSCC [28, 29].
Implementation of intensified and multimodal treatmenthas improved the clinical outcome of HNSCC, but often
causes severe toxicity and debilitating long-term impacts
on quality of life accompanied with only limited clinical
benefit. Accordingly, only 40-50 % of patients with an
advanced disease will survive for five years after primary
treatment [26], and appropriate therapy of advanced
HNSCC still remains a major challenge. Therefore,
prognostic biomarkers are urgently needed for better
stratification of patients with high risk for treatment
failure, and to support the identification of novel drug
targets for more efficient and less toxic therapies.
In the current study, we conducted loss-of-function
and gain-of-function approaches in mucosal tumor
cell lines to investigate the contribution of KLK6 in
the regulation of tumor development and malignant
progression. We demonstrate that silencing of KLK6
expression promotes tumor cell proliferation, migration
and invasion in vitro. This phenotype is accompanied by
the induction of epithelial-to-mesenchymal transition
(EMT), nuclear accumulation of β-catenin and resistance
against irradiation. The clinical relevance of our findings
is supported by the fact that low KLK6 protein level in
primary HNSCCs serves as unfavorable risk factor for
progression-free and overall survival.
Results
KLK6 regulates tumor cell proliferation
KLK6 expression was monitored on transcript and protein
levels in three well-established HNSCC cell lines (FaDu,
Cal27 and SCC25) as well as one cervix carcinoma cell
line (HeLa). KLK6 transcripts were detected in all three
HNSCC cell lines, with highest levels in FaDu cells, while
KLK6 expression was almost not detectable in HeLa cells
(Fig. 1A). KLK6 expression was also evident on protein
level by Western blot analysis, and its presence in the cell
culture supernatant demonstrated efficient secretion by
HNSCC cell lines under normal growth conditions
(Fig. 1A). Following transfection of FaDu cells with control
(FaDu-Mock) or pRS-KLK6-shRNA vectors (FaDu-shKLK6),
we established stable clones as loss-of-function model
to gain a deeper insight into the molecular role of
KLK6 on tumor relevant processes. Semi-quantitative
and quantitative RT-PCR demonstrated efficient silencing
of endogenous KLK6 expression in FaDu-shKLK6 as
compared to mock controls, with the highest residual
KLK6 transcript level in the FaDu-shKLK6#1 clone
(Fig. 1B).
FaDu-shKLK6 clones were characterized by a signifi-
cant increase in the total number of cells over a time
period of six days (Fig. 1C). The degree of the phenotype
was associated with the silencing efficiency and less
prominent for FaDu-shKLK6#1. A decrease in tumor cell
growth was consistent with reduced BrdU incorporation in
FaDu-Mock as compared to FaDu-shKLK6 clones (Fig. 1D).
Fig. 1 Silencing of KLK6 expression in FaDu cells promotes tumor cell proliferation. (A) KLK6 expression in human HNSCC (FaDu, Cal27, SCC25)
and HeLa cervix carcinoma cells was monitored on protein level by Western blot analysis with cell culture supernatants (upper panel), and on
transcript level by semi-quantitative (middle panels) as well as quantitative RT-PCR (lower graph). Detection of LMNB1 amplicons served as
control for cDNA quality and quantity for semi-quantitative RT-PCR (lower panel), while transcript levels of three independent reference genes
(ACTB, LMNB1, TBP) were used for quantitative RT-PCR data. (B) KLK6 expression in stable FaDu-Mock and FaDu-shKLK6 clones is given by
semi-quantitative (upper panel) and quantitative RT-PCR (lower graph) and was determined as described in (A). Differences in tumor cell proliferation
between stable FaDu-Mock and FaDu-shKLK6 clones was monitored by quantification of cell counts over a time period of six days (C) and a BrdU
incorporation assay (D). The graph represents mean values and standard deviations (SD) of the percentage total of BrdU-positive cells from three
independent FaDu-shKLK6 clones and mock controls, respectively
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growth inhibition, we transfected KLK6-negative HeLa
cells with control (HeLa-Mock) or pcDNA-KLK6-Myc/His
plasmids (HeLa-KLK6) to generate stable clones with
ectopic KLK6 overexpression (Additional file 1: Fig. S1A-B).
Indeed, HeLa-KLK6 clones had a significantly reduced
tumor cell growth in comparison to HeLa-Mock controls
(Additional file 1: Fig. S1C).
KLK6 regulates tumor cell morphology, migration and
invasion
Parental FaDu cells and FaDu-Mock controls displayed
an epithelial morphology and grew in well-defined
cell clusters. In contrast, microscopic inspection of
FaDu-shKLK6 clones demonstrated a mesenchymal-
like morphology and intracellular stress fibers, easilydetectable by phalloidin staining (Fig. 2A). These data
suggested a critical impact of KLK6 on tumor cell
motility, which was further supported by an accelerated
migration rate (Fig. 2B-C), as well as an induced invasion
capacity in a matrigel-coated Boyden chamber assay of
FaDu-shKLK6 clones as compared to FaDu-Mock
controls (Fig. 2E-F).
KLK6 expression and epithelial-to-mesenchymal transition
The mesenchymal-like morphology and accelerated
motility of FaDu cells upon loss of KLK6 expression
resembled molecular features of EMT. In line with
this assumption, Western blot analysis demonstrated
an almost complete loss of E-cadherin and prominent
induction of Vimentin expression in FaDu-shKLK6
clones as compared to FaDu-Mock controls (Fig. 3A).
Fig. 2 Accelerated tumor cell migration and invasion by KLK6 silencing. (A) Representative pictures of FaDu-Mock and FaDu-shKLK6 clones
demonstrating a mesenchymal-like morphology (upper panel) after silencing of KLK6 expression accompanied by the presence of stress fibers as
determined by phalloidin IF staining (signal in green). Nuclear staining was done with Hoechst 33324 (blue staining); black bar = 50 μm and white
bar = 50 μm. (B) Representative bright-field pictures of FaDu-Mock and FaDu-shKLK6 clones at the indicated time points of an in vitro migration
assay. Red lines indicate the border of the migration front. Black bar = 500 μm. (C) Differences in tumor cell migration between FaDu-Mock and
FaDu-shKLK6 clones is depicted as relative mean values ± SD of three independent experiments. Gap closure was determined by quantification of
open areas between two borders at the indicated time points, and the value at the time point 0h was set to 100 %. (D) Representative pictures
of invasive FaDu-Mock and FaDu-shKLK6 clones in a matrigel-coated Boyden chamber assay after nuclear staining with Hoechst 33324 (blue staining);
white bar = 50 μm. (E) Quantification of the total amount of invading cells is depicted as mean value ± SD of three independent experiments
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also evident by immunofluorescence staining (Fig. 3B). In
line with these findings, ectopic KLK6 overexpression in
HeLa cells resulted in strongly reduced Vimentin expres-
sion (Additional file 1: Fig. S1D).
Next, we investigated the expression of well-established
regulators of EMT by quantitative RT-PCR with cDNA
derived from FaDu-Mock and FaDu-shKLK6 clones. In
addition to significantly induced Vimentin (VIM) and
reduced E-cadherin (CDH1) transcript levels FaDu-shKLK6
clones showed higher transcript levels for SNAIL1 (SNAI1),
ZEB1, ZEB2, Fibronectin (FN1), and N-cadherin (CDH2)
(Fig. 3C). In contrast, TWIST1 and SLUG (SNAI2)
transcript levels were reduced by KLK6 silencing.
Loss of KLK6 expression induces nuclear β-catenin
accumulation
Protein-protein interaction networks and functional data
indicated that KLK6 might regulate EMT via the TGF-βsignaling pathway [14]. However, neither FaDu cells
with silenced KLK6 expression nor HeLa cells with
ectopic KLK6 expression exhibited major changes in
SMAD2/3 phosphorylation (Additional file 2: Figure S2).
EMT also has been associated with nuclear accumulation
of β-catenin, which is implicated in cell-cell adhesion
and a key component of Wnt signaling [30]. Western
blot analysis demonstrated no major alteration on the
total amount of β-catenin protein in FaDu cells after
KLK6 silencing (Fig. 4A). Next, we investigated its intra-
cellular localization by immunofluorescence staining. As
expected, prominent staining for β-catenin was detected
at the cell membrane of FaDu-Mock controls, while
FaDu-shKLK6 clones were characterized by its nuclear
accumulation (Fig. 4B). Presence of nuclear β-catenin was
accompanied by a strong induction of TCF-dependent
transcription as determined by transient transfection of
two independent FaDu-Mock and FaDu-shKLK6 clones,
respectively, with the TOPFLASH reporter plasmid
Fig. 3 Silencing of KLK6 expression induces an EMT-like phenotype. (A) Western blot analysis with whole cell lysate of FaDu-Mock and FaDu-shKLK6
clones demonstrates differences in E-cadherin and Vimentin protein levels. Detection of β-Actin serves as control for quantity and quality of
protein lysates. (B) Representative pictures of an IF staining confirms Vimentin expression (green signal) in FaDu-shKLK6 but not in of FaDU-Mock
clones. Nuclear staining was done with Hoechst 33324 (blue staining); white bar = 20 μm. (C) Relative transcript levels of the indicated genes was
assessed by quantitative RT-PCR as described above and depicted as mean value + SD of three independent FaDu-Mock and FaDu-shKLK6
clones. *p-value < 0.05, **p-value < 0.005, ***p-value < 0.0005
Schrader et al. Molecular Cancer  (2015) 14:107 Page 5 of 14(Fig. 4C). In summary, activation of Wnt/β-catenin
signaling was associated with the EMT phenotype after
silencing of KLK6 expression and might contribute to an
accelerated self-renewal capacity.
KLK6 expression and radiosensitivity
An increasing body of experimental evidence supports
that an EMT-like phenotype is related to treatment
resistance of tumor cells. To investigate whether silen-
cing of KLK6 alters the radiosensitivity of FaDu cells, we
performed a colony-forming assay. In the absence of
irradiation FaDu-shKLK6 clones developed larger colonies
as compared to mock controls, which was consistent with
an increase in proliferation (Fig. 4D). In addition, the total
number of colonies was higher for FaDu-shKLK6 clones,
which might be due to an increased percentage of cells
with self-renewal capacity as a consequence of Wnt/
β-catenin activity. After irradiation with single doses
of 2 and 5 Gy, respectively, the relative survival fraction
was significantly higher in FaDu cells with silenced KLK6
expression (Fig. 4E), suggesting a higher radiosensitivity of
mock controls.KLK6 protein levels in human oropharyngeal and
laryngeal SCCs
So far, our in vitro data provide experimental evidence
that loss of KLK6 expression supports proliferation,
motility and treatment resistance of cancer cells ori-
ginating from mucosal epithelia, which is-at least in
part-due to the induction of an EMT-like phenotype.
To address the clinical relevance of these findings, we
determined KLK6 protein levels by IHC staining on
tissue microarrays (TMAs) containing tissue samples of
two patient cohorts with primary oropharyngeal (OPSCC)
or laryngeal squamous cell carcinoma (LSCC). Positive
staining was mainly detected in supra-basal keratinocytes
of normal mucosa, while a more heterogeneous staining
pattern ranging from absent to high KLK6 protein levels
in tumor cells was evident in tumor sections (Fig. 5A–C).
Staining specificity was further confirmed by IHC staining
with an independent anti-KLK6 antibody on serial TMA
sections (Additional file 3: Fig. S3). Evaluation of KLK6
expression concerning the relative amount of positive
tumor cells and the staining intensity revealed a final
expression score for 162 patients, including 115 OPSCCs
Fig. 4 Silencing of KLK6 induces β-catenin signaling and radioresistance (A) Western blot analysis with whole cell lysate of FaDu-Mock and
FaDu-shKLK6 clones confirm similar β-catenin protein levels. Detection of β-Actin serves as control for quantity and quality of protein lysates.
(B) Representative pictures of an IF staining demonstrates β-catenin localization (green signal) at the cell membrane of FaDu-Mock controls and
its nuclear accumulation in FaDu-shKLK6 clones. Nuclear staining was done with Hoechst 33324 (blue staining); white bar = 20 μm. (C) Two
independent FaDu-Mock and FaDu-shKLK6 clones were transfected with a TCF-dependent reporter (TOPFLASH) or a mutant control plasmid
(FOPFLASH). The graph represents the relative luciferase activity as mean value + SD of three independent experiments. The value of one
FOPFLASH-transfected mock control was set to one. (D) Representative pictures of a colony forming assay after irradiation with 2 or 5 Gy and of
untreated controls (0 Gy). (E) The graph represents the relative survival fraction after irradiation at the indicated doses, which is displayed as mean
values ± SD and was calculated by the combination of FaDu-Mock#1–3 (red line) and FaDu-shKLK#1-3 (blue line). *p-value < 0.05, ***p-value < 0.0005
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patient subgroups with KLK6high (n = 69) and KLK6low
(n = 93) protein levels for further analysis. In the
combined patient cohort KLK6 protein expression did
not correlate with any of the clinical or pathological
features tested, including age, TNM status, clinical
stage, pathological grade, and main risk factors, with
the exception of gender as females were significantly
enriched in the KLK6low patient subgroup (Table 1).
Moreover, KLK6 expression was significantly associated
with the pathological grade, which was restricted to the
LSCC cohort and the HPV status in the OPSCC cohort
(Additional file 4: Figure S4).
To address the question, whether KLK6 expression
serves as prognostic biomarker for clinical outcome, we
performed Kaplan Meier analysis for progression-free(PFS) and overall survival (OS) of patients in the combined
cohort (Fig. 5D–E). The 5-year survival rate for the
KLK6low subgroup was 37 % (PFS) and 44 % (OS),
respectively, as compared to 65 % (PFS) and 70 % (OS) for
the KLK6high subgroup. Accordingly, KLK6low protein
staining was significantly associated with reduced PFS
(p-value = 0.001) and OS (p-value <0.0005) as compared to
patients with KLK6high expression pattern. Kaplan Meier
analysis for the individual LSCC and OPSCC patient
cohorts revealed similar data (Additional file 5: Table S3)
(Additional file 5: Table S4). Next, we performed univariate
and multivariate Cox regression analysis to confirm that
KLK6low expression serves as an independent risk factor for
unfavorable clinical outcome (Table 2) (Additional file 5:
Table S5). Finally, we performed IHC staining on serial
tumor sections to investigate inverse regulation of KLK6
Fig. 5 Low KLK6 expression is a risk factor for unfavorable overall and progression-free survival. Representative pictures of an IHC staining on
tissue sections of normal mucosa (A) and primary HNSCC (B–C) demonstrates tumor samples with low (B) and high (C) KLK6 protein expression
(brown signal). Counterstaining with hematoxylin to visualize tissue architecture; black bar = 100 μm. Association between KLK6 protein staining
and overall survival (D), or progression-free survival (E) was assessed by univariate Kaplan-Meier analysis. Green line = subgroup with high KLK6
staining pattern and blue line = subgroup with low KLK6 staining pattern. Representative pictures of IHC staining (brown signal) demonstrate
inverse regulation of KLK6 and Vimentin protein expression (F), or KLK6-related differences in cellular β-catenin localization (G) on serial tumor
sections. Inlets represent larger magnifications to demonstrate prominent staining of β-catenin at the membrane or its nuclear accumulation.
Counterstaining with hematoxylin to visualize tissue architecture; scale bar = 100 μm. T = tumor and S = stromal tissue
Schrader et al. Molecular Cancer  (2015) 14:107 Page 7 of 14and Vimentin as well as intracellular accumulation of
β-catenin in tumor cells with KLK6low expression levels
(Fig. 5F–G).
In summary, these data demonstrate a close association
between loss of KLK6 expression and worse clinical
outcome of LSCC and OPSCC patients, and strongly
support the assumption that KLK6 might serve as a reliable
prognostic biomarker to identify HNSCC patients at high
risk for treatment failure.Discussion
Aberrant expression of KLK6 is a common feature for many
human malignancies and numerous studies evaluated KLK6
as a prognostic biomarker (reviewed in [3]). Consistent with
most reports, we found high KLK6 expression in primary
tumor samples of 42.6 % HNSCC patients. However, while
induced KLK6 expression alone or in combination with
other KLK family members was associated with poor
progression-free and overall survival in colorectal cancer
Table 1 Correlation analysis for KLK6 protein expression and
clinico-pathological features of the combined HNSCC cohort
KLK6low KLK6high p-value
Age [years] <58.62 50 30 0.128
≥58.62 43 39
Gender male 69 60 0.035
female 24 9
Tumor size T1/2 39 30 0.509
T3/4 53 39
missing1 1
Lymph node status N0 27 27 0.129
N+ 65 42
missing1 1
Distant metastasis M0 87 67 0.287
M+ 4 1
missing1 2 1
Clinical stage I/II 16 12 0.581
III/IV 76 57
missing1 1
Pathological grade G1/2 46 42 0.319
G3 29 21
missing1 18 6
Smoking status non-smoker 10 9 0.400
smoker2 82 58
missing1 1 2
Alcohol consumption non-drinker 8 9 0.219
drinker3 83 55
missing1 2 5
1 data missing; 2 former and current smokers; 3 former and current drinkers.
Significant p-values (<0.05) are indicated in bold
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cinoma [35], ovarian cancer [36, 37], lung cancer [38], and
intracranial tumors [39, 40], a high KLK6 expression pattern
served as favorable prognostic biomarker in our OPSCC
and LSCC patient cohorts. These data suggest a context-
specific role of KLK6 in regulating the malignant progres-
sion and response to therapy, with both tumor promoting
and tumor protective functions depending on the cellular
origin of the tumor tissue. However, it is worth noting
that the tumor promoting function of KLK6 in most
human cancers has been deduced from the association of
its expression and clinical or pathological features.
But only few studies address the underlying molecular
mechanisms in vitro, and confirmations in preclinical
model systems are missing.
So far, only two studies investigated the prognostic
value of other KLKs in laryngeal cancer, while to the best of
our knowledge no study was published on oropharyngealSCCs. Both studies reported a remarkable down-regulation
of either KLK4 or KLK11 transcript levels in laryngeal
cancer as compared to their non-malignant counter-
parts [41, 42]. Similar to our data on KLK6, patients with
KLK11-positive tumors had a favorable prognosis [41], and
low KLK4 expression predicted short-term relapse and
poor disease-free survival [42]. Finally, down-regulation
of KLK13 was reported in oral SCC cell lines and low
KLK13 expression in primary oral cancer significantly
correlated with regional lymph node metastasis [43, 44].
A tumor protective role of KLK6 was demonstrated in
breast cancer, where it was identified originally as a putative
tumor suppressor due to its down-regulation during metas-
tasis [22]. Tumor-specific loss of KLK6 expression in breast
cancer cells is mediated by epigenetic silencing initiated by
hyper-methylation at the proximal promoter [14]. It will be
interesting to address whether a similar mode of regulation
also occurs in primary HNSCC with low KLK6 expression,
and in local recurrence or metastasis that develop in
HNSCC patients with treatment failure.
Pampalakis and colleagues demonstrated that restoration
of physiological KLK6 levels in breast cancer cell lines
reverted the malignant phenotype in vitro and in vivo [14].
They provided compelling evidence that KLK6 may
act as suppressor for tumor progression by promoting
a mesenchymal-to-epithelial transition [14]. In line
with our findings in HeLa cells, reactivation of KLK6
in breast cancer cells was associated with prominent
down-regulation of Vimentin in the absence of a parallel
rise in E-cadherin (unpublished data). These data suggest
a common inhibitory function of KLK6 on Vimentin
expression in breast and mucosal epithelial cells; however,
the molecular mechanism remains to be fully elucidated.
Moreover, silencing of KLK6 in a HNSCC cell line with
prominent KLK6 expression resulted in an EMT-like
phenotype with strong up-regulation of Vimentin,
complete loss of E-cadherin and deregulation of other
well-established molecular markers of EMT. On the
cellular level loss of KLK6 was associated with accelerated
migration and invasion as well as impaired response to
irradiation, well-known characteristics of EMT and most
likely responsible for the poor clinical outcome of HNSCC
patients with low KLK6 expression. Our data are in con-
trast to recent findings in other tumor cells lines derived
from skin and colon cancer in which KLK6 promotes
tumor cell migration and invasion by either E-cadherin
ectodomain shedding [45], activation of protease-activated
receptors [8] or so far unknown molecular mechanisms
[46]. Although the principle nature for these cell type
specific differences remains elusive, Pampalakis and
colleagues claimed that KLK6 regulates EMT in breast
cancer cells via the TGF-β pathway [14, 47]. However,
neither FaDu cells with silenced KLK6 expression nor
HeLa cells with ectopic overexpression exhibited obvious
Table 2 Multivariate analysis of overall and progression-free survival for HNSCC patients of the combined cohort
Risk factor Overall Survival Progression-Free Survival
HR (95 % CI) p-value HR (95 % CI) p-value
KLK6
low vs. high1 2.793 (1.498–5.209) 0.001 2.236 (1.291–3.873) 0.004
Age [years]
<58.621 vs. ≥58.62 1.588 (0.892–2.825) 0.116 1.359 (0.811–2.277) 0.244
Gender
male1 vs. female 0.571 (0.268–1.219) 0.148 0.567 (0.281–1.143) 0.112
Clinical stage
I/II1 vs. III/IV 2.333 (0.892–6.104) 0.084 1.621 (0.724–3.629) 0.240
Pathological grade
G1/21 vs. G3 0.811 (0.431–1.527) 0.517 1.135 (0.648–1.987) 0.658
smoking
non-smoker1 vs. smoker2 1.701 (0.602–4.808) 0.317 2.831 (1.013–7.912) 0.047
Alcohol consumption
non-drinker1 vs. drinker3 0.911 (0.343–2.418) 0.852 1.056 (0.440–2.535) 0.903
1 variable set as reference; 2 former and current smokers; 3 former and current drinkers. Significant p-values (<0.05) are indicated in bold. HR hazard ratio, CI
confidence interval
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major impact of KLK6 on canonical TGF-β signaling, at
least in mucosal tumor cells. Intriguingly, our study
demonstrated nuclear accumulation of β-catenin and
activation of TCF-dependent gene expression upon
KLK6 silencing in FaDu cells. Nuclear accumulation
of β-catenin was also evident in KLK6low tumor samples
of HNSCC patients. Intracellular expression of β-catenin
has been reported in the context of invasive growth and
metastasis of oral carcinoma cells as well as poor prognosis
[48]. β-catenin is a component of the cell-cell adhe-
sion complex and anchored to cadherin-related pro-
teins, which sequester β-catenin at the cell periphery.
Consequently, nuclear accumulation of β-catenin
might result from down-regulation of E-cadherin
during EMT after silencing of KLK6 in vitro or loss
of E-cadherin expression in KLK6low tumor cells
during malignant progression of HNSCCs. In addition,
β-catenin is also a key regulator of the Wnt signaling.
Wnt/β-catenin is one of the crucial pathways in the
maintenance of the self-renewal capacity of stem cells,
and its inhibition is a promising approach to target cancer
stem cells from HNSCC [49, 50]. In contrast to our
data, KLK6-induced nuclear translocation of β-catenin
was demonstrated in mouse keratinocytes and human lung
cancer cell lines in vitro [45, 51], further supporting a
diverse and context dependent function of KLK6 in
malignant progression.
Conclusion
In summary, our data demonstrate for the first time that
low KLK6 expression serves as unfavorable risk factorfor progression-free and overall survival of HNSCC
patients, and we provide experimental evidence that
KLK6 is a key regulator of tumor cell migration, invasion
and response to radiotherapy by modulating EMT and
β-catenin signaling (Fig. 6). However, it remains a major
challenge for the future to unravel relevant direct targets
for KLK6 proteolysis and affected signaling networks
that causally contribute to the observed phenotype in
mucosal but also breast cancer cells. Furthermore, it will
be worth to establish and investigate appropriate pre-
clinical models in order to proof the concept, whether
HNSCC patients with low KLK6 expression might bene-
fit from pharmacological restoration of KLK6 expression
or specific targeting of EMT-related pathways, such as
Wnt/β-catenin signaling. This could pave the way for
biomarker-driven clinical trials for HNSCC but also
other tumor entities in the near future.
Methods
Cell culture experiments
Human HNSCC cell lines (FaDu, Cal27 and SCC25
purchased from ATCC) and the cervix carcinoma cell
line HeLa were maintained in Dulbecco’s Modified
Eagle’s Medium (Sigma, Germany) supplemented with 10 %
fetal bovine serum (Sigma, Germany), 2 mM L-Glutamine
(Sigma, Germany) and 50 μg/ml Penicillin-Streptomycin
(Sigma, Germany) in a humidified atmosphere of 6-8 %
CO2 at 37 °C. Authentication of all cell lines was confirmed
by the Multiplex Human Cell Line Authentication Test
(Multiplexion, Germany).
FaDu cells were transfected with either a control pRS
vector encoding a non-effective Hush 29-mer scrambled
Fig. 6 Summary of alterations in molecular, cellular and functional
features of HNSCC cells after loss of KLK6 expression. Silencing of KLK6
expression induces an EMT-like phenotype characterized by loss of
E-cadherin and gain of Vimentin expression (indicated in green) as
well as nuclear accumulation of β-catenin (indicated in red). As a
consequence, KLK6-negative tumor cells exhibit increased proliferation,
motility and radioresistance, which is in line with the poor clinical
outcome of HNSCC patients with low KLK6 expression
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a pRS-shKLK6 plasmid (TR316673, OriGene Technologies,
USA) using FuGene HD Transfection Reagent (Promega,
Germany) according to the manufacturer’s instruction.
Following selection with 1.5 μg/ml Puromycin (Gibco life
technologies, Germany) for one week, stable clones were
isolated and KLK6 silencing was confirmed on RNA
level. HeLa cells were transfected with either the
pcDNA3.1-Myc/His control or pcDNA3.1-KLK6-Myc/His
expression plasmids using FuGene HD Transfection
Reagent (Promega, Germany) according to the manu-
facturer’s instruction. Cloning of pcDNA-KLK6-Myc/His
plasmid was described previously [45]. Following selection
with 0.4 mg/ml Neomycin (Calbiochem Merck, Germany)
for two weeks, stable single clones were isolated and
ectopic KLK6 expression was confirmed on RNA and
protein level.
Tumor cell growth and proliferation
1,000 cells per well were seeded in 12-well plates. At the
indicated time points after seeding, cells were trypsinized,
stained with trypan blue and total number of living cells
was determined with the help of a Neubauer counting
chamber. For the BrdU cell proliferation assay, 20,000cells per well were seeded on glass coverslips in 12-well
plates. 48 hours after seeding, cells were treated for
30 minutes with 1 mM BrdU, washed three times
with 1xPBS for five minutes, and fixed for seven minutes
with cold methanol (-20 °C). After intense washing with
1xPBS, fixed cells were treated for 30 minutes at 37 °C with
2M HCl, followed by incubation in borate buffer for
10 minutes. After intense washing with 1xPBS, samples
were incubated for 30 minutes at RT with 10 % goat serum
in 0,1 % Triton-X-100 in PBS. Next, samples were incu-
bated overnight and at 4 °C with the Alexa555-conjugated
BrdU-antibody (diluted 1:100 in PBS). After intense
washing with 1xPBS stained cells were incubated with
Hoechst 33342 (Calbiochem Merck, Germany) for five
minutes and mounted with Mowiol.
Phalloidin and immunofluorescence staining
20,000 cells per well were seeded on glass coverslips in a
12-well plate. 48 hours after seeding, cells were fixed
with 4 % PFA for 15 minutes, treated for 30 minutes with
0.5 % Triton-X100 in PBS, and incubated for 30 minutes
with 0.2 % Tween 20/1 % BSA in TBS. Following incubation
for 1–2 hours at RT with the first antibody diluted in 0.2 %
Tween/1 %BSA in TBS, the secondary antibody diluted in
0.2 % Tween/1 % BSA in TBS was added. After incubation
for 30–60 minutes at RT, nuclei were visualized by
incubation of cells with Hoechst 33342 (Calbiochem Merck,
Germany) and cytoskeleton rearrangement was visualized
by incubation with Phalloidin-Alexa Fluor 488 (Invitrogen,
Germany) as described previously [45]. Finally coverslips
were mounted with Mowiol. Reagents and antibodies used
are listed in Additional file 5: Table S2.
Migration and invasion assay
To assess tumor cell migration, 21,000 cells were seeded
into each chamber of sterile culture inserts (ibidi, Germany),
which were placed in 6-well plates. 12 hours after seeding,
cells were treated for one hour with 10 μg/ml Mitomycin C
(Sigma, Germany) in the incubator and insert were
removed. Pictures were taken with the Nikon Eclipse
Ti microscope using the Nikon Imaging Software
NIS-Elements 3.20.02 at the indicated time points and
analyzed with the software tool ImageJ to quantify the
kinetic of gap closure over time.
To determine tumor cell invasion, FaDu-shKLK6 and
FaDu-Mock cells were treated for one hour with 10 μg/ml
Mitomycin C (Sigma, Germany), trypsinized and 100,000
cells were seeded in matrigel-coated Boyden chamber
inserts (BD Bioscience, Germany), which were placed
in 12-well plates. After 48 hours, non-invading cells
were removed using cotton swaps and remaining cells
were fixed for ten minutes in 4 % PFA and stained
with Hoechst 33342 (Calbiochem Merck, Germany).
Following mounting with Mowiol, five representative
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using the Nikon Imaging Software NIS-Elements 3.20.02,
and the amount of invaded cells was counted with the
software tool ImageJ.Colony forming assay
To determine the response to irradiation, 100, 300
and 1,000 cells were seeded per well in 6-well plates
and irradiated at a dose of 2 or 5 gray (Gy) using X-RAD
320 (Precision X-Ray, North Branford, CT USA) or kept
untreated as controls. After 9 days in culture, clones were
stained with crystal violet and total number of colonies
was quantified as described in [52]. The survival fraction
was computed according to [53].RNA extraction, cDNA synthesis and RT-PCR analysis
Total RNA from tumor cell lines was isolated with the
RNeasy Mini Kit (Qiagen, Germany) following the
manufacturer’s instruction. DNA digestion was performed
with RNase-free DNAse Set (Qiagen, Germany). Quantity
and quality of isolated RNA was determined with the help
of the Nanodrop Spectrophotometer ND-1000 (peqlab,
Germany). For cDNA synthesis 5 μg total RNA were di-
luted in 35 μl nuclease-free H2O. 0.5 μl Oligo (dT) primers
were added and incubated for five minutes at 70 °C. A mix-
ture of 10 μl 5xRevertAid Buffer, 2 μl 25 mM dNTP mix, 2
μl Ribolock RNase Inhibitor and 0.5 μl RevertAid Reverse
Transcriptase (all from Fermentas, Germany) was added
per reaction and incubated for one hour at 42 °C. For semi-
quantitative RT-PCR a ready-to-use mix (Red Load Taq
Master, Jena Bioscience, Germany) was used according to
manufacturer’s instructions. Amplicons were separated by
1 % agarose gel electrophoresis and visualized with GelRed
(Biotium, USA) using the UV documentation system for
agarose gel (peqlab, Germany). Quantitative RT-PCR was
performed as described previously [54]. As reference genes
transcript levels of ACTB, LMNB1 and TBP were quanti-
fied. Specific annealing temperatures and sequences of all
primers are listed in Additional file 5: Table S1. The cycle of
threshold (CT) of the gene of interest was standardized to
the CT values of the reference genes (ACTB, LMNB and
TBP) using the ΔΔCT method. For each primer pair, pri-
mer efficiency was tested by a dilution series from 0.01 to
100 ng of a cDNA mix of all samples. A primer efficiency
of 1.8 to 2.0 was accepted for further analysis.Western blot analysis
Western blot analysis was performed with whole cell
lysates or enriched protein fractions from cell culture
supernatants as described previously [45]. Antibodies
and dilutions that were used for Western blot analysis
are listed in Additional file 5: Table S2.Luciferase reporter assay
30,000 FaDu-Mock and FaDu-shKLK6 cells were seeded
in 24-well plates and transfected with either 0.3 μg
TOPFLASH or 0.3 μg FOPFLASH (upstate biotech-
nology, USA) using FuGene HD Transfection Reagent
(Promega, Germany) according to the manufacturer’s
instruction. As reference for transfection efficiency all cells
were co-transfected with 0.3 μg pTK-RL (Promega,
Germany). Firefly and Renilla luciferase activity was quan-
tified with a Sirius Luminometer (Berthold Detection
Systems, Germany) using the Dual-Luciferase Reporter
Assay System (Promega, Germany) and according to the
manufacturer’s instruction.
Patient material
The retrospective study cohort included laryngeal (LSCC)
and oropharyngeal squamous cell carcinoma (OPSCC)
patients, who were treated at the University Hospital
Heidelberg between 1990 and 2008. Paraffin-embedded
tissue specimens were provided by the tissue bank of the
National Center for Tumor Disease (Institute of Pathology,
University Hospital Heidelberg) after approval by the local
institutional review board (ethic vote: 206/2005). The study
was performed according to the ethical standards of the
Declaration of Helsinki. For all tumor samples, clinical and
follow-up data were available from the Department of
Otolaryngology, Head and Neck Surgery at the University
Hospital Heidelberg.
Tissue microarray and IHC staining
TMAs were generated as previously described [55].
Briefly, hematoxylin and eosin stained sections were cut
from each donor block and a certified pathologist defined
representative tumor regions. Small tissue cylinders with a
diameter of 0.6 mm were taken from selected areas of each
donor block using a tissue chip micro-arrayer (Beecher
Instruments, Silver Spring, MD, USA) and transferred to a
recipient paraffin block. The recipient paraffin block was
cut in 2 μm paraffin sections using standard techniques.
Immunohistochemistry was conducted with an anti-
KLK6 antibody (R&D Systems, Germany) listed in
Additional file 5: Table S2 using the TSA Amplification Kit
(Perkin Elmer, Germany) according to the manufacturer’s
instruction. Counterstaining was done with hematoxylin to
visualize tissue integrity.
TMAs were scanned using the Nanozoomer HT Scan
System (Hamamatsu Photonics, Japan) capable of scanning
whole slides. The Nanozoomer HT Scan System generates
digital images of full tissue sections, allowing large-scale
histologic evaluation across the complete section. The slides
were scanned at a 40-fold magnification (0.23 μm/pixel).
Three experienced observers analyzed scanned slides
without prior knowledge on the expected results
using the NDP Viewer software (version 1.1.27). The
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two independent categories: first, the number of
stained tumor cells (ranging from 1 to 4: score 1 = no
positive cells, score 2 = less than 33 %, score 3 = between
34 and 66 %, and score 4 =more than 66 % positive cells),
and second, the staining intensity (ranging from 1 to 4:
score 1 = no staining, score 2 = weak staining, score
3 = moderate staining, and score 4 = high staining).
Subsequently, both scores were multiplied resulting
in the final expression score ranging from 1–16, and
patient subgroups were arranged according to KLK6high or
KLK6low expression.Statistical analysis
Statistical analysis was done using SPSS (version 21) and
SAS (version 9.3) statistics software. Differences between
groups were assessed using Chi square test. Overall
survival (OS) was calculated as the time from the date of
primary tumor diagnosis to the date of cancer-related
death within the follow-up interval (events). Survival
times of patients who were alive or were dead due to
causes other than cancer were censored. Progression-free
survival (PFS) was calculated from the date of primary
tumor diagnosis to the date of the first local recurrence,
lymph node or distant metastasis, second primary car-
cinoma, or date of cancer-related death within the
follow-up period (events). Patients without progression
(no event) or cancer-unrelated death were censored. The
method of Kaplan-Meier was used to estimate survival
distributions. Differences between groups were deter-
mined by log-rank tests. A multivariate Cox proportional
hazard model was used to assess the association between
KLK6 expression scores and overall and progression-free
survival of cancer patients from both cohorts, together
with the covariates age (continuous variable), clinical stage
(IV vs. I–III), gender (female vs. male), TNM, grading,
alcohol and tobacco consumption (never vs. former and
current consumer). The validity of the proportional
hazards assumption was tested with the Supreme Test
for proportional hazards assumption and was met for
all covariates. In all statistical tests, a p-value of 0.05
or below was considered as statistically significant.Additional files
Additional files 1: Figure S1. Decreased tumor cell growth and
Vimentin expression in HeLa cells with ectopic KLK6 expression. KLK6
transgene expression in stable HeLa clones was confirmed on transcript
level by semi-quantitative RT-PCR (A) and on protein level by Western
blot analysis (B). Detection of LMNB1 amplicons served as control for
cDNA quality and quantity for semi-quantitative RT-PCR, while detection
of β-Actin served as control for quantity and quality of protein lysates.
(C) Differences in tumor cell growth between stable HeLa-Mock and
HeLa-KLK6 clones were monitored by quantification of cell counts over a
time period of one week. (D) Western blot analysis with whole cell lysateof HeLa-Mock and HeLa-KLK6 clones demonstrates reduced Vimentin
protein levels in the presence of ectopic KLK6 expression.
Additional files 2: Figure S2. KLK6 expression has no impact on
canonical TGFβ signaling. Western blot analysis with whole cell lysate of
FaDu-Mock and FaDu-shKLK6 clones (A) or HeLa-Mock and HeLa-KLK6 clones
(B) were conducted with anti-pSMAD2/3 or anti-SMAD2 antibodies. Detection
of β-Actin served as control for quantity and quality of protein lysates.
Additional files 3: Figure S3. Confirmation of staining specificity by
IHC staining with two independent anti-KLK6 antibodies. Representative
pictures of an IHC staining (brown signal) with two independent anti-KLK6
antibodies (A and C, AF2008 from R&D; B and D, sc20264 from Santa Cruz)
on serial TMA sections with primary HNSCC samples. Counterstaining with
hematoxylin to visualize tissue architecture; black bar = 100 μm.
Additional files 4: Figure S4. KLK6 protein staining serves as risk factor
for unfavorable progression-free and overall survival of LSCC and OPSCC
patients. Association between KLK6 protein staining and overall survival
(A and C) or progression-free survival (B and D) was assessed by univariate
Kaplan-Meier analysis for the LSCC (A–B) and OPSCC patient cohort (C–D).
Green line = subgroup with high KLK6 staining pattern and blue line =
subgroup with low KLK6 staining pattern.
Additional files 5: Table S1. List of primer sequences for RT-PCR
analysisTable S2. List of primary (A) and secondary antibodies (B)
Table S3. Correlation analysis for KLK6 protein expression and clinical and
pathological features of the LSCC cohort. Table S4. Correlation analysis for
KLK6 protein expression and clinical and pathological features of the
OPSCC cohort. Table S5. Univariate Cox regression analysis of overall and
progression-free survival for HNSCC patients of the combined cohort.
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